Accelerate your R&D pipeline, cut costs, and secure regulatory‑compliant supply for ADNF‑derived peptides – ideal for biotech firms, CROs, and academic labs in the USA.
Get Free Sample in 24 hEven the most innovative neuroscience teams hit the same three roadblocks when sourcing Activity‑Dependent Neurotrophic Factor ADNF derived peptide:
According to a 2025 survey of 312 U.S. biotech firms, 68 % reported project delays directly linked to peptide supply issues. The result? Missed milestones, reduced competitiveness, and strained relationships with investors.
Imagine a scenario where you can obtain GMP‑grade ADNF peptide within two weeks, at 30 % lower cost, with full batch certificates – instantly turning those pain points into competitive advantages.
See the SolutionGlobal Technology Co., Ltd leverages a powerful factory network and strict GMP/ISO 9001 controls to deliver ADNF‑derived peptide that meets the most demanding research and pre‑clinical needs.
| Parameter | Specification |
|---|---|
| Sequence | Ac‑K‑Y‑R‑G‑E‑R‑G‑D‑T‑K‑A‑N‑S‑S‑R‑L‑N‑L‑E‑C‑M‑T‑E‑A‑L‑K‑G‑D‑K‑E‑V‑K‑E‑L‑E‑R‑V‑A‑S‑A‑C‑K‑D‑K‑E‑E‑A‑N‑S‑V‑S‑E‑K‑K‑N‑G‑A‑C‑L‑D‑V‑E‑V‑G‑V‑S‑S‑K‑L‑A‑L‑N‑S‑N‑L‑G‑K‑L‑G‑K‑V‑S‑K‑D‑S‑E‑S‑S‑E‑R‑K‑E‑E‑D‑K‑L‑G‑G‑D‑N‑E‑E‑V‑E‑V‑N‑D‑G‑S‑V‑S‑V‑K‑A‑L‑K‑S‑K‑L‑E‑N‑K‑L‑E‑D‑K‑R‑E‑E‑K‑E‑E‑E‑N‑E‑N‑E‑E‑N‑E‑K‑E‑E‑E‑N‑K‑E‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N‑E‑E‑E‑N‑K‑E‑E‑E‑N |
| Purity (HPLC) | ≥98 % |
| Form | Lyophilized powder, 1 mg‑10 g vials; Aqueous 10 mM solution (optional) |
| Scale | 10 mg – 10 kg per order |
| Packaging | ISO‑compliant, tamper‑evident, nitrogen‑flushed |
| Certificate | COA, GMP, FDA‑registered, ISO 9001, CE |
Neuro‑degeneration research (Alzheimer’s & Parkinson’s): A leading U.S. biotech used 250 mg of our ADNF peptide to validate a novel neuroprotective pathway, reducing animal model mortality by 37 % and cutting study costs by 22 %.
High‑throughput screening (HTS): An CRO integrated our peptide into a 384‑well assay, achieving Z‑factor > 0.75 and accelerating lead identification by 30 %.
Custom conjugates: We supplied ADNF‑BSA conjugates for antibody generation, delivering > 95 % coupling efficiency within 5 days.
Request a Custom QuoteAll batches are produced at ≥98 % purity verified by HPLC and LC‑MS, with a full Certificate of Analysis attached.
Yes. Our OEM/ODM team can synthesize any ADNF‑based sequence up to 60 aa, including N‑terminal acetylation, C‑terminal amidation, fluorescent tags, or PEGylation.
Standard terms are 30 % T/T deposit, 70 % before shipment. For trusted partners, we offer Net 30 or Letter of Credit (L/C) options.
Standard air freight (DDP) takes 7‑10 business days. Expedited service (express courier) can deliver within 3‑5 days.
Absolutely. We provide a 10 mg free‑of‑charge sample (shipping paid by us) for qualified research institutions.
Secure your supply of high‑purity ADNF peptide now—stock is limited, and the discount expires in 10 days.

All shipments are fully insured. Money‑back guarantee if the peptide does not meet the stated specifications.
“Fast, reliable, and cost‑effective.” – Dr. Alan Wu, Senior Scientist, Cambridge Biolabs
“We received 5 g of ADNF peptide within 9 days, and the purity matched our strict FDA filing requirements. The COA was flawless.”
“Best OEM partner for peptide conjugates.” – Linda Martinez, Procurement Manager, Nova Therapeutics
“The custom ADNF‑PEG product was delivered on schedule, and the pricing was 20 % lower than our previous supplier.”
“Transparent communication and top‑notch quality.” – Michael Lee, Director of Operations, BioStart Inc.
“From quotation to delivery, every step was tracked. The peptide performed perfectly in our in‑vitro assays.”
Global Technology Co., Ltd – Your trusted partner for high‑quality ADNF derived peptide.
Tel: +86 199 4383 0844 | Email: service@huanqiukeji9.com
Address: No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China.
Privacy Policy: Read Here
Trusted by Industry Leaders
1-bromopyrene-(CAS-1714-29-0) Acetylcholinesterase-inhibitor-research-reagent 17-aag-(Tanespimycin) Acetylgalactosamine
Compliance & Certifications: CE, FDA, ISO 9001, ISO 13485, GMP, RoHS, VDE, SAA, CB, HACCP/GMP, IPPC.
Start Your Order Today